Why Missing Safety Narratives Remain a Major Regulatory Audit Concern

Introduction: The Role of Safety Narratives

Safety narratives are integral components of pharmacovigilance reporting, providing a detailed description of individual Serious Adverse Events (SAEs) or Suspected Unexpected Serious Adverse Reactions (SUSARs). They include clinical context, chronology, medical assessments, and outcomes, enabling regulators to evaluate causality and risk.

Regulatory agencies such as the FDA, EMA, and MHRA expect sponsors to provide comprehensive narratives as part of expedited reporting, Development Safety Update Reports (DSURs), and final Clinical Study Reports (CSRs). Missing or incomplete safety narratives are among the most common audit findings, often categorized as major deficiencies because they compromise the ability of regulators to assess drug safety accurately.

Regulatory Expectations for Safety Narratives

According to ICH E2A and ICH E3 guidelines, narratives should provide:

• A clear chronological account of the adverse event.
• Patient demographics and baseline medical history.
• Details of the investigational product, dosing, and exposure.
• Clinical course, investigations, treatments, and outcomes.
• Sponsor and investigator causality assessments.

These narratives must be available for all SAEs and SUSARs and incorporated into regulatory submissions. The U.S. Clinical Trials Registry highlights that comprehensive safety narratives are critical for transparency and regulatory review.

Common Audit Findings on Missing Safety Narratives

1. Absent Narratives in DSURs

Auditors often identify DSURs that include cumulative safety data but omit narratives for key SAEs or SUSARs. This is considered a major compliance gap.

2. Incomplete Narratives

Some narratives lack important clinical details, such as laboratory results, diagnostic imaging, or outcome documentation. Such omissions weaken the scientific value of the report.

3. Delayed Narrative Updates

Follow-up data is sometimes missing from safety narratives, leaving the case incomplete at the time of submission.

4. CRO Oversight Failures

When CROs prepare narratives, sponsors sometimes fail to verify completeness, resulting in missing or inconsistent data across submissions.

Case Study: EMA Audit Findings on Missing Narratives

In a Phase III immunology trial, EMA inspectors found that 10 SUSARs were reported without narratives, while another 15 had incomplete medical details. The deficiency was classified as critical because it prevented regulators from conducting a full causality assessment. The sponsor was required to resubmit corrected narratives, retrain staff, and implement a narrative quality review process.

Root Causes of Missing Safety Narratives

Audit investigations frequently identify the following systemic root causes:

• Lack of standardized templates for narrative preparation.
• Inadequate training of pharmacovigilance and medical writing teams.
• Over-reliance on CROs without strong sponsor oversight.
• Time pressures leading to submission of incomplete narratives.
• Poor integration between clinical and pharmacovigilance databases.